Prostatype Genomics AB announces full subscription

Last night, Prostatype Genomics AB announced that the company has achieved full subscription of its rights issue with the help of top guarantors.

Even though the development in Prostatype Genomics AB over the past 9 month does not live up to our expectations, LSIF participated for part of our holdings to support the crucial mission of getting Medicare approval.

We now hope to see in the near future that Prostatype Genomics AB demonstrates its ability to handle the process with Medicare professionally and bring it to a positive outcome.